NCT02273362View on ClinicalTrials.gov

Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 24, 2014

Primary Completion Date

February 11, 2020

Study Completion Date

March 10, 2022

Conditions
CirrhosisHepatocellular Carcinoma
Interventions
DRUG

Erlotinib

Given PO

DRUG

Erlotinib Hydrochloride

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Quality-of-Life Assessment

Ancillary studies

Trial Locations (6)

10029

Mount Sinai Hospital, New York

44106

Case Western Reserve University, Cleveland

44195

Cleveland Clinic Foundation, Cleveland

55905

Mayo Clinic in Rochester, Rochester

32224-9980

Mayo Clinic in Florida, Jacksonville

02114

Massachusetts General Hospital Cancer Center, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT02273362 - Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver | Biotech Hunter | Biotech Hunter